3,350 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Chesapeake Capital Corp IL

Chesapeake Capital Corp IL acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,350 shares of the life sciences company’s stock, valued at approximately $448,000.

A number of other large investors have also recently bought and sold shares of ILMN. Golden State Wealth Management LLC bought a new stake in shares of Illumina during the 4th quarter worth approximately $32,000. Versant Capital Management Inc raised its position in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Illumina during the fourth quarter worth $45,000. Assetmark Inc. lifted its stake in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 296 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its holdings in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ILMN has been the subject of several recent analyst reports. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Robert W. Baird dropped their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Piper Sandler lifted their price target on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Guggenheim lowered their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Canaccord Genuity Group cut their target price on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Stock Performance

NASDAQ:ILMN opened at $85.16 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a fifty-two week low of $80.18 and a fifty-two week high of $156.66. The company has a 50 day simple moving average of $111.38 and a two-hundred day simple moving average of $129.20. The company has a market capitalization of $13.49 billion, a PE ratio of -11.09, a P/E/G ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.